- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA to Pull Approval of 2 Drugs Used in Combo With Statins
The action, to be published Monday in the Federal Register, comes as the agency puts increased focus on long-term safety of drugs that treat diabetes and obesity, and prevent cardiovascular events.
On Monday, FDA will withdraw approvals for 2 medications that had been used with statins to treat high levels of cholesterol. The pending decision was listed in documents ready for publication in the Federal Register and was first reported by Medscape.
The affected therapies, both sold by AbbVie, are niacin extended release (Niaspan) and fenofibric acid (Tripilix). The order will also affect the combination therapies Advicor, which combines niacin with lovastatin, and Simcor, which combines niacin with simvastatin.
This unusual step is a result of FDA’s increased attention to long-term safety effects of medications for diabetes, obesity, and to prevent heart disease. Documentation with the notice lists results from several trials, including those from ACCORD, AIM-HIGH, and the HPS2-THRIVE Collaboration Group. The agency said the evidence "no longer supports the conclusion that a drug-induced reduction in triglyceride leels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events."
FDA’s pending withdrawal notice states that that agency asked AbbVie to voluntarily stop marketing Advicor and Simcor and the company agreed, waiving its right for a hearing.
“The agency has also determined that Advicor and Simcor were withdrawn from sale for reasons of safety and effectiveness, and FDA will not accept or approve abbreviated drug applications that reference Advicor and Simcor,” the notice states.
Niacin extended-release (Niaspan) received approval in 1997. Advicor was subsequently approved to treat hypercholesterolemia, both familial and nonfamilial, as well as mixed dyslipidemia for patients whose triglycerides or low-density lipoprotein (LDL) cholesterol levels remain high on less-intense therapy.
Simcor was approved in 2008 to treat total cholesterol levels, apolipoprotein B, triglycerides or to raise HDL or “good” cholesterol in patients with hypercholesterolemia and mixed dyslipidemia.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More
